Pfizer (PFE) to Acquire Arena Pharmaceuticals (ARNA) for $100 Per Share, $6.7 Billion Deal
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/10/2026
- Wall St steadies ahead of South Korean chip bellwether SK Hynix's debut
- Oil heads for weekly gains as Middle East supply risks persist
- The real reason Meta shares are surging has nothing to do with its new AI model
- Stifel lifts Shopify to Buy, sees agentic commerce as next growth catalyst
- Delta Air Lines stock climbs on earnings beat and strong guidance
- Key things to know ahead of SK Hynix’s blockbuster US listing
- Almonty Industries (ALM) PT Raised to $33 at DA Davidson
- S&P Downgrades Oracle To 'bbb-/A-3'; Outlook Stable
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- Software stocks slide as Starbucks builds AI tools to replace vendor software
Pfizer’s (PFE) $6.7B Arena Acquisition is Priced Reasonably, May Offer Additional Upside, Pfizer Making Good Use of Cash – Analyst
December 13, 2021 9:30 AM ESTEarlier today, Pfizer Inc. (NYSE: PFE) and Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced that the companies have entered into a definitive agreement under which Pfizer will acquire Arena. Under the terms of the agreement, Pfizer will acquire all the outstanding shares of Arena for $100 per share in an all-cash transaction for a total equity value of approximately... More
Low Valuations to Drive Pharma M&A in 2022 - Analyst
December 13, 2021 8:50 AM ESTIn light of recently announced major biotech acquisitions - Dicerna (NASDAQ: DRNA) was acquired by Novo Nordisk (NYSE: NVO) for $38 (~80% premium) and Arena (NASDAQ: ARNA) now being acquired for $100/sh (~100% premium) by Pfizer... More
